Shah Rajeev M. 4
4 · Eidos Therapeutics, Inc. · Filed May 29, 2020
Insider Transaction Report
Form 4
Shah Rajeev M.
Director
Transactions
- Award
Stock Option (right to buy)
2020-05-27+21,528→ 21,528 totalExercise: $48.51Exp: 2030-05-27→ Common Stock (21,528 underlying)
Footnotes (2)
- [F1]The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended).
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Manager"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Account to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.